Clinical trial NCT05027646: Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Official title: A Randomized, Open-Label, Replicate Treatment, 2-Part, Crossover Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches Manufactured at Different Sites.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Patch
Nausea
Anti-emetic
Granisetron
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: PPD Development, LP
First posted: 2021-08-30
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: This is a single-center, randomized, 2-part, open-label, crossover study in healthy subjects to establish BE (Part 1) and evaluate adhesion (Part 2) between granisetron transdermal patches.
Primary purpose: PREVENTION

Brief summary: The study is designed to evaluate the BE and adhesion properties of granisetron transdermal patches manufactured at 2 different sites. The study has been designed in accordance with the FDA Guidance for Industry. Bioequivalence will be based on the Cmax and AUC to determine the peak and total drug exposure, respectively.

Detailed description: This is a single-center, randomized, 2-part, open-label, crossover study in healthy subjects to establish bioequivalence (Part 1) and evaluate adhesion (Part 2) between granisetron transdermal patches manufactured at 2 different sites (Sancuso \[test\] and Sancuso \[reference\]).

Each part of the study will consist of a screening period, check-in days, treatment periods, washout period (Part 1 only), and an end-of-study visit. The duration of subject participation, excluding screening, for Part 1 is approximately 39 days and for Part 2 is approximately 17 days.

Eligibility criteria: Inclusion Criteria:

* Male or female 18 to 55 years, inclusive
* BMI 18 to 30 kg/m2
* Healthy volunteers, health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results and physical examination.
* Agrees to comply with all protocol requirements.
* Able to provide written and voluntary informed consent.
* Female participants of childbearing potential have a negative pregnancy test and agree to adhere to an acceptable methods of birth control.
* Male participants with female partners of childbearing potential agree to acceptable methods of birth control.

Exclusion Criteria:

Participant to be excluded if,

* Presents with baseline systolic blood pressure \>140 mm Hg and diastolic blood pressure \>90 mm Hg.
* Any clinically significant ECG finding or QTcF interval \>450 msec for males and \>470 msec for females.
* A history of sensitivity to granisetron or other components of the transdermal patch.
* Pregnant or breastfeeding.
* Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results, as determined by the investigator.
* Participants with following pre-existing liver functioning test elevations will be excluded: alanine aminotransferase or aspartate aminotransferase elevation \>2 × ULN, and/or bilirubin \>2 × ULN
* Acute or chronic renal or hepatic impairment, that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results, as determined by the investigator.
* Acute or chronic psychiatric condition, including, but not limited to compulsive-depressive disorders, anxiety, and/or sleep disorders that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results.
* A history of coronary heart disease, arterial or pulmonary hypertension, supraventricular or ventricular tachycardias, or other arrhythmias or heart rhythm and conduction disorders.
* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or HIV types 1 or 2 antibodies at screening.
* If used any prescription (excluding hormonal birth control) or over the counter medications (except paracetamol \[up to 2 g per day\]), including herbal or nutritional supplements, within 14 days before the first application of the transdermal patch.
* If used 5-HT3 receptor antagonists and other serotonergic drugs (eg, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and IV methylene blue) within 14 days before the first application of the transdermal patch.
* If used antihistamines within 72 hours prior to patch application or systemic or topical corticosteroids within 3 weeks before the first application of the transdermal patch.
* Present with a dermatological disorder at any relevant patch application site that precludes proper placement or may interfere with adhesion, site assessment, or potentially affect drug absorption.
* Has allergies or other contraindications to transdermal systems or patch adhesives or to medical adhesive tape, adhesive dressings, or other skin patches.
* If not willing to allow hair to be removed or clipped at the proposed patch application sites that may prevent proper placement of the patch.
* If presents with and has oily skin or any skin problems such as being damaged (cut or scraped) or irritated (redness or a rash) at the application sites.
* If consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or alcohol-, caffeine-, or xanthine containing products within 48 hours before the first application
* The subject is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 3 months before the first application of the transdermal patch.
* If has a history of alcohol abuse or drug addiction within a year.
* If presents with a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking).
* If involved in strenuous activity or contact sports within 24 hours before the first application and during the study.
* If donated blood or blood products \>450 mL within 30 days before the first application.
* If has a history of relevant drug and/or food or significant food allergy that could preclude a standard diet in the CRU.
* If received study drug in another investigational study within 30 days of the first application.
* In the opinion of the investigator, the subject is not suitable for entry into the study.

Primary outcomes:
measure: Area under the plasma concentration versus time curve AUC (0-t)
timeFrame: 6 months
measure: Area under the plasma concentration versus time curve AUC (0-inf)
timeFrame: 6 months
measure: Peak Plasma Concentration (Cmax)
timeFrame: 6 months
measure: Maximum concentration (Tmax)
timeFrame: 6 months
measure: T1/2
timeFrame: 6 months
measure: CL/F
timeFrame: 6 months
measure: Vz/F
timeFrame: 6 months
measure: Mean adhesion score (FDA scale)
timeFrame: 6 months
Secondary outcomes:
measure: Number of subjects with treatment related adverse events will be as assessed as mild, moderate or severe and will be summarized descriptively and presented as frequency and percentage.
timeFrame: 6 Months
measure: Adhesion performance score (FDA Scale)
timeFrame: 6 Months
Other outcomes:
Locations:
city: Austin
country: United States
facility: PPD Development
state: Texas
Study officials:
References:
citation: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations (DHHS 2014). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). March 2014
citation: Guidance for Industry: Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs (DHHS 2018). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) October 2018